Brian Stuglik, Verastem CEO
The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline
When Infinity put up duvelisib for a no-money-down instant deal, the biotech was looking for a quick exit from a clinical disaster. AbbVie had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
